Indeed if UK approves and CYDY has commercial supp
Post# of 148181
It makes a lot of sense that MHRA wants to know how much LL they can have before they approve.
I don't think CYDY would give them the entire commercial supply, but perhaps CYDY has no reason to give UK everything.
This is certainly a "path to market" that could be discussed in one hour.
I have no clue what sale restrictions might or might not exist in this situation.
But surely both the FDA and the MHRA know exactly what the situation is.
So when the FDA meets with CYDY tomorrow, surely the FDA must know that the UK may take a big bite out of the LL supply the next day. Surely the FDA must be aware of this possibility.
Its interesting that CYDY published both the FDA and MHRA meeting dates simultaneously. We don't know which agency meeting was scheduled first, which might indicate whether or not the second meeting was scheduled in response to the first meeting.
If UK is ready to run, it makes sense for CYDY to say to the FDA, "Hey, MHRA is ready to talk "path to market", do you want to talk about that?"